我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

匹伐他汀与阿托伐他汀对冠状动脉旁路移植术后早期患者调节血脂的对比研究

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2018年第4期
页码:
415-417,429
栏目:
临床研究
出版日期:
2018-04-25

文章信息/Info

Title:
Comparative study between pitavastatin and atorvastatin in lowering blood lipid in patients early after coronary artery bypass graft
作者:
冯 翔; 姜 睿; 王少也; 许建屏; 杨 研; 潘世伟
（国家心脏病中心中国医学科学院阜外医院成人心脏外科，北京 100037）
Author(s):
FENG Xiang;  JIANG Rui;  WANG Shao-ye;  XU Jian-ping;  YANG Yan;  PAN Shi-wei
(Department of Cardiovascular Surgery, Fuwai Hospital, Chinese Academy of Medical Science, Beijing 100037, China)
关键词:
匹伐他汀; 阿托伐他汀; 冠状动脉旁路移植术; 血脂
Keywords:
pitavastatin;  atorvastatin;  coronary artery bypass graft;  blood lipid
分类号:
R972
DOI:
-
文献标识码:
A
摘要:
目的 对比匹伐他汀（2 mg）和阿托伐他汀（20 mg）对冠状动脉旁路移植术(CABG)后早期血脂控制的效果及安全性。方法 以单中心非盲随机对照的方式对196位受试者开展为期12周的临床研究。结果 术后12周匹伐他汀组和阿托伐他汀组的总胆固醇（TC）,低密度脂蛋白胆固醇(LDL-C)和三酰甘油（TG）较基线水平均显著降低（均P<0.05）,但组间无显著差异；两组患者的高密度脂蛋白胆固醇（HDL-C）较基线水平有所升高（P<0.05），但组间无显著差异；术后1周时，两组的丙氨酸氨基转氨酶（ALT）,门冬氨酸氨基转氨酶（AST）及肌酸激酶(CK)较基线水平均有所升高，但阿托伐他汀组的ALT及CK较匹伐他汀组更高；术后12周匹伐他汀组的ALT,AST及CK较基线水平无显著变化，阿托伐他汀的ALT及CK较基线水平增高，但两组间无显著差异。结论 2 mg匹伐他汀与20 mg阿托伐他汀有相似的降低TC,LDL-C,TG及升高HDL-C的作用。
Abstract:
AIM To evaluate the efficacy and safety of pitavastatin (2 mg) and atorvastatin (20mg) in lowering blood lipids in coronary artery bypass graft (CABG) patients. METHODS An open-blind randomized control trial was conducted in single cardiac center with 196 CABG patients for 12 weeks. RESULTS TC, LDL-C and TG levels at the 12th week after CABG decreased significantly compared with baseline (P<0.05). There were no differences between the two groups. HDL-C levels increased at the 12th week when compared with baseline (P<0.05). There were no differences between the two groups. ALT, AST and CK levels increased at the 1st week when compared with baseline and the ALT and CK levels were higher in the atorvastatin group. ALT, AST and CK levels were no different to baseline levels at the 12th week after CABG in the pitavastatin group, but ALT and CK levels in the atorvastatin group were higher when compared with baseline. CONCLUSION Pitavastatin is a safe and effective medication for lowering blood lipid in patients after CABG. Pitavastatin (2 mg) and atorvastatin (20 mg) can achieve similar effects in decreasing TC, LDL-C and TG levels and increasing HDL-C levels.

参考文献/References

[1]Kulik A,Ruel M,Jneid H,et al.Secondary prevention after coronary artery bypass graft surgery:a scientific statement from the American Heart Association[J].Circulation,2015,131(10):927-964.

[2]Saito Y,Yamada N,Teramoto T,et al.A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia[J].Atherosclerosis,2002,162(2):373-379.

[3]Lee SH,Chung N,Kwan J,et al.Comparison of the efficacy and tolerability of pitavastatin and atorvastatin:an 8-week,multicenter,randomized,open-label,dose-titration study in Korean patients with hypercholesterolemia[J].Clin Ther ,2007,29(11):2365-2373.

[4]毛 勇,余金明,战义强，等.匹伐他汀治疗高胆固醇血症安全性和有效性的多中心观察[J].中华医学杂志,2012,92(14):968-937.

[5]毛 勇，余金明，张 芬，等.匹伐他汀对血糖的效应及其治疗糖尿病高胆固醇血症的疗效[J].中华内科杂志,2012,51(7):508-512.

[6]Nawrocki JW,Weiss SR,Davidson MH,et al.Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor[J].Arterioscler Thromb Vasc Biol,1995,15(5):678-682.

[7]Bakker-Arkema RG,Davidon MH,Goldstein RJ,et al.Efficacy and safety of a new HMG-CoA redutase inhibitor, atorvastatin,in patients with hypertriglyceridemia[J].JAMA,1996,275(2):128-133.

[8]Shah SJ,Waters DD,Barter P,et al.Intensive Lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery[J].J Am Coll Cardiol,2008,51(20):1938-1943.

[9]Ooyen C,Zecca A,Bersino AM,et al.NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor,decreases apolipoprotein B-100 secretion from Hep G2 cells[J].Atherosclerosis,1999,145(1):87-95.

[10]Suzuki H,Aoki T,Tamaki T,et al.Hypolipidemic effect of NK-104(Pitavastatin),a potent HMG-CoA reductase inhibitor,in guinea pigs[J].Atherosclerosis,1999,146(2):259-270.

[11]Kajinami K,Koizumi J,Ueda K,et al.Effects of NK-104,a new hydroxyl-methylglutaryl-coenzyme reductase inhibitor,on low density lipoprotein cholesterol in heterozygous familial hyper-cholesterolemia.Hokuriku NK-104 Study Group[J].Am J Cardiol,2000,85(2):178-183.

[12]Yokote K,Bujo H,Hanaoka H,et al.Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention(CHIBA study)[J].Atherosclerosis,2008,201(2):345-352.

[13]Sansanayudh N,Wongwiwatthananukit S,Putwai P,et al.Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia[J].Ann Pharmacother,2010,44(3):415-423.

[14]Edwards JE,Moore RA.Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomized, double blind trials[J].BMC Fam Pract,2003,4:18.

[15]Maruyama T,Takada M,Nishibori Y,et al.Comparison of preventive effect on cardiovascular events with different statins.the CIRCLE study[J].Circ J,2011,75(8):1951-1959.

[16]Nozue T,Michishita I.Statin treatment alters serum n-3 to n-6 polyunsaturated fatty acids ratio in patients with dyslipidemia[J].Lipids Health Dis,2015,14:67.

备注/Memo

备注/Memo:
收稿日期：2017-05-25.通讯作者：姜睿,副主任医师，主要从事危重症冠心病和肺动脉高压研究 Email:jiangruifw@aliyun.com 作者简介：冯翔，主治医师，博士生 Email：381656381@qq.com
更新日期/Last Update: 1900-01-01